Skip to content

US · CAMP · BIOTECHNOLOGY

CAMP4 Therapeutics Corporation (CAMP) intrinsic value and stock valuation

$3.79as of 2026-11-21 · Mkt cap 90.06M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CAMP4 Therapeutics Corporation DCF and intrinsic value

InvestorsCraft values CAMP with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CAMP’s statements →

CAMP4 Therapeutics Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 camp4tx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.5M-60.5% 5y CAGRd
20112025
Net income
-$-80.4M
20112025
Free cash flow
-$-29.83M
20112025
Total equity
$47.7M-19.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.5M$650K$350K$295.8M$308.6M
Operating income-$-52.06M-$-53.09M-$-51.88M-$-15.31M-$-3.87M
Net income-$-80.4M-$-51.79M-$-49.29M-$-31.15M-$-21.16M
EPSd-$-2.65M-$-2.65M-$-4.07M-$-883.69K-$-615.3K
Operating cash flow-$-29.55M-$-45.56M-$-44.16M-$-4.22M$28.6M
Capital expenditure-$-280K-$-440K-$-680K-$-13.3M-$-11.36M
Free cash flow-$-29.83M-$-46M-$-44.83M-$-17.52M$17.2M
Total assets$117.8M$78.3M$55M$402.3M$441.8M
Total debt$1.97M$8.65M$11.7M$209.2M$210.8M
Net debt-$-107.54M-$-55.39M-$-26.69M$118.1M$119.1M
Total equity$47.7M$63.1M-$-123.73M$80.2M$99.3M
Cash and short-term investments$109.5M$64M$38.4M$91.1M$91.7M
Income statement
20252024202320222021
Revenue$3.5M$650K$350K$295.8M$308.6M
Cost of revenue$1.64M$0.00$0.00$174M$186.2M
Gross profit$1.86M$650K$350K$121.9M$122.4M
Research and development expenses$38.2M$38.8M$40.6M$28.4M$25.8M
Selling, general and administrative expenses$17.4M$14.9M$11.6M$100.9M$95.3M
Other expenses-$-1.64M$0.00$0.00$5.42M$4.78M
Operating expenses$53.9M$53.7M$52.2M$134.8M$125.9M
Cost and expenses$55.6M$53.7M$52.2M$308.7M$312.1M
Interest income$2.17M$1.33M$2.81M$0.00$0.00
Interest expense$0.00$0.00$0.00$15.3M$15.5M
Depreciation and amortization$1.64M$1.7M$1.68M$22.8M$22M
Ebitda-$-50.42M-$-51.39M-$-50.2M$7.49M$18.1M
Operating income-$-52.06M-$-53.09M-$-51.88M-$-15.31M-$-3.87M
Total other income/expenses, net-$-28.34M$1.3M$2.59M-$-14.75M-$-16.73M
Income before tax-$-80.4M-$-51.79M-$-49.29M-$-30.06M-$-20.6M
Income tax expense$0.00$0.00$0.00$1.09M$560K
Net income-$-80.4M-$-51.79M-$-49.29M-$-31.15M-$-21.16M
Weighted average shares outstanding$30.4M$19.5M$12.1M$35.3M$34.1M
Weighted average diluted shares outstanding$30.4M$19.5M$12.1M$35.3M$34.4M
Balance sheet
20252024202320222021
Cash and short-term investments$109.5M$64M$38.4M$91.1M$91.7M
Net receivables$150K$110K$440K$58.6M$67.9M
Inventory$0.00$0.00$0.00$20.2M$32.2M
Total current assets$114.1M$66.4M$40M$193.6M$215.2M
Property, plant and equipment, net$2.74M$10.3M$13.3M$50.1M$62.2M
Goodwill and intangible assets$0.00$0.00$0.00$127M$133.4M
Long-term investments$890K$0.00$0.00$24.3M$24.2M
Total non-current assets$3.71M$11.9M$14.9M$208.7M$226.6M
Total assets$117.8M$78.3M$55M$402.3M$441.8M
Accounts payable$180K$1.21M$1.04M$30.8M$36.8M
Short-term debt$290K$3.08M$3.06M$7.74M$10.9M
Deferred revenue$9.39M$390K$0.00$32.4M$38.9M
Total current liabilities$15.5M$9.6M$7.81M$94.9M$107.4M
Long-term debt$1.69M$5.56M$8.63M$201.4M$199.9M
Deferred revenue, non-current$8.11M$0.00$0.00$14.5M$24.2M
Total non-current liabilities$54.6M$5.57M$170.9M$227.2M$235.1M
Capital lease obligations$0.00$8.65M$11.7M$0.00$0.00
Total liabilities$70.1M$15.2M$178.7M$322.1M$342.5M
Common stock$10K$0.00$0.00$360K$350K
Retained earnings-$-292.16M-$-211.75M-$-159.96M-$-156.78M-$-129.25M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-2.44M-$-1.11M
Total equity$47.7M$63.1M-$-123.73M$80.2M$99.3M
Total investments$890K$0.00$0.00$24.3M$24.2M
Total debt$1.97M$8.65M$11.7M$209.2M$210.8M
Net debt-$-107.54M-$-55.39M-$-26.69M$118.1M$119.1M
Cash flow statement
20252024202320222021
Net income-$-80.4M-$-51.79M-$-49.29M-$-27.99M-$-56.31M
Depreciation and amortization$1.64M$1.7M$1.68M$22.8M$22M
Stock-based compensation$4M$4.03M$2.91M$11.3M$11.4M
Change in working capital$13M-$-1.88M-$-150K$1.59M$11M
Accounts receivable$0.00$0.00$0.00$1.44M$1.62M
Inventory$0.00$0.00$0.00$5.16M$8.69M
Accounts payable-$-1.03M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-29.55M-$-45.56M-$-44.16M-$-4.22M$28.6M
Investments in property, plant and equipment-$-280K-$-440K-$-680K-$-13.3M-$-11.36M
Acquisitions, net$40K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-240K-$-440K-$-680K-$-7.58M-$-13.69M
Common stock issued$61.2M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$75.9M$71.7M$300K-$-2.64M-$-27.32M
Net change in cash$46.1M$25.7M-$-44.53M-$-15.4M-$-12.78M
Cash at end of period$111.8M$65.7M$40M$79.2M$94.6M
Operating cash flow-$-29.55M-$-45.56M-$-44.16M-$-4.22M$28.6M
Capital expenditure-$-280K-$-440K-$-680K-$-13.3M-$-11.36M
Free cash flow-$-29.83M-$-46M-$-44.83M-$-17.52M$17.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CAMP4 Therapeutics Corporation

        CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

        CEO
        Joshua Mandel-Brehm
        Employees
        48
        Beta
        0.21

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of CAMP4 Therapeutics Corporation (CAMP)?

        CAMP4 Therapeutics Corporation (CAMP) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CAMP undervalued?

        CAMP trades at a price of $3.79 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.